ASCO: Teclistamab Improves Survival in Relapsed, Refractory Multiple Myeloma

TUESDAY, June 2, 2026 -- For patients with relapsed or refractory multiple myeloma, teclistamab monotherapy significantly improves progression-free and overall survival, according to a study published online May 29 in the New England Journal of...